TRAIL and Chemotherapeutic Drugs in Cancer Therapy

Asakuma, 2003, Selective Akt inactivation and tumor necrosis factor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel, Cancer Res., 63, 1365 Ashkenazi, 1998, Death receptors: Signaling and modulation, Science, 281, 1305, 10.1126/science.281.5381.1305 Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest., 104, 155, 10.1172/JCI6926 Ashkenazi, 1999, Apoptosis control by death and decoy receptors, Curr. Opin. Cell Biol., 11, 255, 10.1016/S0955-0674(99)80034-9 Bodmer, 2000, Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL, J. Biol. Chem., 275, 20632, 10.1074/jbc.M909721199 Bodmer, 2000, TRAIL receptor-2 signals apoptosis through FADD and caspase-8, Nat. Cell Biol., 2, 241, 10.1038/35008667 Bonavida, 1999, Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (review), Int. J. Oncol., 15, 793 Chai, 2000, Structural and biochemical basis of apoptotic activation by Smac⧸DIABLO, Nature, 406, 855, 10.1038/35022514 Chaudhary, 1997, Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway, Immunity, 7, 821, 10.1016/S1074-7613(00)80400-8 Chawla-Sarkar, 2002, IFN-beta pretreatment sensitizes human melanoma cells to TRAIL⧸Apo2 ligand-induced apoptosis, J. Immunol., 169, 847, 10.4049/jimmunol.169.2.847 Cuello, 2001, Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2, Cancer Res., 61, 4892 Cuello, 2001, Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells, Gynecol. Oncol., 81, 380, 10.1006/gyno.2001.6194 Degli-Esposti, 1997, Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family, J. Exp. Med., 186, 1165, 10.1084/jem.186.7.1165 Dejosez, 2000, Sensitivity to TRAIL⧸APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan, Cell Death Differ., 7, 1127, 10.1038/sj.cdd.4400746 Emery, 1998, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J. Biol. Chem., 273, 14363, 10.1074/jbc.273.23.14363 Engels, 2000, Caspase-8⧸FLICE functions as an executioner caspase in anticancer drug-induced apoptosis, Oncogene, 19, 4563, 10.1038/sj.onc.1203824 Evdokiou, 2002, Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L⧸TRAIL-induced apoptosis, Int. J. Cancer, 99, 491, 10.1002/ijc.10376 French, 1999, The TRAIL to selective tumor death, Nat. Med., 5, 146, 10.1038/5505 Fulda, 2002, Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression, Oncogene, 21, 2283, 10.1038/sj.onc.1205258 Gibson, 2000, Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL, Mol. Cell. Biol., 20, 205, 10.1128/MCB.20.1.205-212.2000 Gliniak, 1999, Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11, Cancer Res., 59, 6153 Griffith, 1998, Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells, J. Immunol., 161, 2833 Grotzer, 2000, Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression, Oncogene, 19, 4604, 10.1038/sj.onc.1203816 Havell, 1988, The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity, J. Exp. Med., 167, 1067, 10.1084/jem.167.3.1067 Hengartner, 2000, The biochemistry of apoptosis, Nature, 407, 770, 10.1038/35037710 Hernandez, 2001, Sensitization of human colon cancer cells to TRAIL-mediated apoptosis, J. Gastrointest. Surgery, 5, 56, 10.1016/S1091-255X(01)80014-7 Hernandez, 2001, Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis, Surgery, 130, 265, 10.1067/msy.2001.115897 Hinz, 2000, Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis, Oncogene, 19, 5477, 10.1038/sj.onc.1203936 Hymowitz, 2000, A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L⧸TRAIL, Biochemistry, 39, 633, 10.1021/bi992242l Ichikawa, 2001, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity, Nat. Med., 7, 954, 10.1038/91000 Irmler, 1997, Inhibition of death receptor signals by cellular FLIP, Nature, 388, 190, 10.1038/40657 Jazirehi, 2001, Adriamycin sensitizes the adriamycin-resistant 8226⧸Dox40 human multiple myeloma cells to Apo2L⧸tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis, Clin. Cancer Res., 7, 3874 Jo, 2000, Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand, Nat. Med., 6, 564, 10.1038/75045 Johnsen, 1999, Regulation of APO-2 ligand⧸trail expression in NK cells-involvement in NK cell-mediated cytotoxicity, Cytokine, 11, 664, 10.1006/cyto.1999.0489 Kagawa, 2001, Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene, Cancer Res., 61, 3330 Kayagaki, 1999, Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs, J. Exp. Med., 189, 1451, 10.1084/jem.189.9.1451 Kayagaki, 1999, Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity, J. Immunol., 162, 2639 Keane, 1999, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer Res., 59, 734 Kim, 2000, Molecular determinants of response to TRAIL in killing of normal and cancer cells, Clin. Cancer Res., 6, 335 Kischkel, 2000, Apo2L⧸TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5, Immunity, 12, 611, 10.1016/S1074-7613(00)80212-5 Kothny-Wilkes, 1998, Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand, J. Biol. Chem., 273, 29247, 10.1074/jbc.273.44.29247 Kuang, 2000, FADD is required for DR4- and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts, J. Biol. Chem., 275, 25065, 10.1074/jbc.C000284200 Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res., 61, 1645 Lawrence, 2001, Differential hepatocyte toxicity of recombinant Apo2L⧸TRAIL versions, Nat. Med., 7, 383, 10.1038/86397 Lee, 2001, Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells, Oncogene, 20, 1476, 10.1038/sj.onc.1204225 Leverkus, 2000, Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes, Cancer Res., 60, 553 Li, 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, 94, 491, 10.1016/S0092-8674(00)81590-1 Luo, 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, Cell, 94, 481, 10.1016/S0092-8674(00)81589-5 MacFarlane, 1997, Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL, J. Biol. Chem., 272, 25417, 10.1074/jbc.272.41.25417 Mariani, 1998, Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage, Eur. J. Immunol., 28, 973, 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T Mariani, 1998, Surface expression of TRAIL⧸Apo-2 ligand in activated mouse T and B cells, Eur. J. Immunol., 28, 1492, 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X Marsters, 1997, A novel receptor for Apo2L⧸TRAIL contains a truncated death domain, Curr. Biol., 7, 1003, 10.1016/S0960-9822(06)00422-2 Martinez-Lorenzo, 1998, Involvement of APO2 ligand⧸TRAIL in activation-induced death of Jurkat and human peripheral blood T cells, Eur. J. Immunol., 28, 2714, 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9 Matsuzaki, 2001, Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells, Clin. Cancer Res., 7, 407 Medema, 1997, FLICE is activated by association with the CD95 death-inducing signaling complex (DISC), EMBO J., 16, 2794, 10.1093/emboj/16.10.2794 Miyazaki, 2001, A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins, Nat. Immunol., 2, 493, 10.1038/88684 Mizutani, 1999, Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells, Clin. Cancer Res., 5, 2605 Mizutani, 1995, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody, Cancer Res., 55, 590 Mizutani, 2001, Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin, J. Urol., 165, 263, 10.1097/00005392-200101000-00076 Mizutani, 2002, Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil, Eur. J. Cancer, 38, 167, 10.1016/S0959-8049(01)00339-2 Mongkolsapaya, 1998, Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL, J. Immunol., 160, 3 Monleon, 2001, Differential secretion of Fas ligand- or APO2 ligand⧸TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells, J. Immunol., 167, 6736, 10.4049/jimmunol.167.12.6736 Mori, 1999, Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D, J. Immunol., 162, 5616 Munshi, 2001, TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2, Oncogene, 20, 3757, 10.1038/sj.onc.1204504 Munshi, 2002, Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells, Cancer Chemother. Pharmacol., 50, 46, 10.1007/s00280-002-0465-z Nagane, 2000, Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res., 60, 847 Nagane, 2001, The potential of TRAIL for cancer chemotherapy, Apoptosis, 6, 191, 10.1023/A:1011336726649 Nagata, 1997, Apoptosis by death factor, Cell, 88, 355, 10.1016/S0092-8674(00)81874-7 Naka, 2002, Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice, Cancer Res., 62, 5800 Ng, 2002, Synergy is achieved by complementation with Apo2L⧸TRAIL and actinomycin D in Apo2L⧸TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance, Prostate, 53, 286, 10.1002/pros.10155 Nimmanapalli, 2001, Pretreatment with paclitaxel enhances apo-2 ligand⧸tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels, Cancer Res., 61, 759 Ogasawara, 1993, Lethal effect of the anti-Fas antibody in mice, Nature, 364, 806, 10.1038/364806a0 Orth, 1996, Molecular ordering of apoptotic mammalian CED-3⧸ICE-like proteases, J. Biol. Chem., 271, 20977, 10.1074/jbc.271.35.20977 Pan, 1997, The receptor for the cytotoxic ligand TRAIL, Science, 276, 111, 10.1126/science.276.5309.111 Pan, 1997, An antagonist decoy receptor and a death domain-containing receptor for TRAIL, Science, 277, 815, 10.1126/science.277.5327.815 Petak, 2001, Shared pathways: Death receptors and cytotoxic drugs in cancer therapy, Pathol. Oncol. Res., 7, 95, 10.1007/BF03032574 Pitti, 1996, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family, J. Biol. Chem., 271, 12687, 10.1074/jbc.271.22.12687 Rieger, 1998, APO2 ligand: A novel lethal weapon against malignant glioma?, FEBS Lett., 427, 124, 10.1016/S0014-5793(98)00409-8 Schneider, 2000, Apoptosis induced by death receptors, Pharmacol. Acta Helv., 74, 281, 10.1016/S0031-6865(99)00038-2 Screaton, 1997, TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL, Curr. Biol., 7, 693, 10.1016/S0960-9822(06)00297-1 Seol, 2001, Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Caspase-8 is required for TRAIL-induced apoptosis, Cancer Res., 61, 1138 Sheridan, 1997, Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors, Science, 277, 818, 10.1126/science.277.5327.818 Sprick, 2000, FADD⧸MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2, Immunity, 12, 599, 10.1016/S1074-7613(00)80211-3 Sun, 2000, Cancer Res., 60, 7149 Sun, 2001, Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells, Biochem. Biophys. Res. Commun., 280, 788, 10.1006/bbrc.2000.4218 Takeda, 2001, Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells, Nat. Med., 7, 94, 10.1038/83416 Tang, 2000, Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis, J. Biol. Chem., 275, 9303, 10.1074/jbc.275.13.9303 Tartaglia, 1992, Two TNF receptors, Immunol. Today, 13, 151, 10.1016/0167-5699(92)90116-O Thomas, 1998, TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells, J. Immunol., 161, 2195 Thomas, 2000, TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria, J. Immunol., 165, 5612, 10.4049/jimmunol.165.10.5612 Verhagen, 2000, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, Cell, 102, 43, 10.1016/S0092-8674(00)00009-X Voelkel-Johnson, 2002, Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL⧸Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL, Cancer Gene Ther., 9, 164, 10.1038/sj.cgt.7700420 Wajant, 2002, TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy, Apoptosis, 7, 449, 10.1023/A:1020039225764 Walczak, 1997, TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL, EMBO J., 16, 5386, 10.1093/emboj/16.17.5386 Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med., 5, 157, 10.1038/5517 Wang, 2001, The expanding role of mitochondria in apoptosis, Genes Dev., 15, 2922 Wei, 2001, Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death, Science, 292, 624, 10.1126/science.1059108 Wen, 2000, Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells, Blood, 96, 3900, 10.1182/blood.V96.12.3900 Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8 Wu, 2000, Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin, Cancer Res., 60, 2912 Wu, 2002, Doxorubicin enhances TRAIL-induced apoptosis in prostatic cancer, Int. J. Oncol., 20, 949 Wu, 2003, Enhancement of TRAIL⧸Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells, Int. J. Cancer, 104, 409, 10.1002/ijc.10948 Yamada, 1999, TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells, Biochem. Biophys. Res. Commun., 265, 130, 10.1006/bbrc.1999.1641 Yamanaka, 2000, Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines, Hepatology, 32, 482, 10.1053/jhep.2000.16266 Zamai, 1998, Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells, J. Exp. Med., 188, 2375, 10.1084/jem.188.12.2375 Zhang, 1999, Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma, Cancer Res., 59, 2747 Zou, 1999, An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9, J. Biol. Chem., 274, 11549, 10.1074/jbc.274.17.11549